BEIJING, May 27 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) (''Lotus'' or the ''Company''), a pharmaceutical company in the People's Republic of China ("PRC"), today announced that it will conduct a conference call at 10:00 a.m. Eastern Time on Tuesday, May 27, 2008 to discuss the first quarter 2008 results.
Joining Mr. Zhongyi Liu, Chairman and Chief Executive Officer of Lotus Pharmaceuticals, will be Mr. Adam Wasserman, Chief Financial Officer.
To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 888-481-7939. International callers should dial 617-847-8707, Conference Passcode: 45954238.
If you are unable to participate in the call at this time, a replay will be available for seven days starting on May 27, at 11:00 a.m. Eastern Time. To access the replay, dial 888-286-8010, international callers dial 617-801-6888, and enter the passcode of 82020022.
About Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc. (''Lotus'') controls and operates Liangfang
Pharmaceutical, Ltd. (''Liangfang'') and Enze Jiashi Pharmaceutical, Ltd.
(''En ze''), two Chinese pharmaceutical companies located in Beijing
(together ''Lotus East''). Lotus East is a comprehensive enterprise, which
deals in an integration of the production, trade, sales and marketing of
pharmaceuticals. The Company possesses some of the most advanced
pharmaceutical-production equipment used in China, workshops authenticated
by the National GMP, a suite of various medicines produced by Lotus East,
and a number of high-tech personnel. Lotus East has business and office
facilities of 2,000 square meters, warehouse of 1,000 square meters and
operates ten retail pharmacies in the Beijing area. Lotus East performs
scientific research on new medicines, and the production, wholesale and
retail sale of medicines through 10 retail pharmacy location t
'/>"/>
| SOURCE Lotus Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |